Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardioneuroablation vs Midodrine for Vasovagal Syncope (CAMPAIGN)
NCT05803148Recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Apr 2023
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Randomised, open-label trial in vasovagal syncope, sponsored by National Center for Cardiovascular Disease. Primary endpoint: Syncope recurrence at 12 months. Started Apr 2023; status: recruiting.
02
Conditions
vasovagal syncope
Beyond the preview
Go deeper on NCT05803148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05803148.